CD34 Stem Cell Boost in Pediatric Allogeneic Stem Cell Transplant Recipients: A Case Series and Review of Literature

Overview

Journal Clin Hematol Int

Specialty Hematology

Date 2023 Apr 7

PMID 37027103

Authors

Sara Bowman

Joe Stanek

Rajinder Bajwa

Veronika Polishchuk

Rolla Abu-Arja

Hemalatha G Rangarajan

Affiliations

Soon will be listed here.

Abstract

Patients with poor graft function (PGF) or declining donor chimerism (DC) post allogeneic hematopoietic cell transplantation (HCT) may benefit from a CD34-selected stem cell boost (SCB). We retrospectively studied outcomes of fourteen pediatric patients (PGF: 12 and declining DC: 2), with a median age of 12.8 (range 0.08-20.6) years at HCT, who received a SCB. Primary and secondary endpoints included resolution of PGF or improvement in DC (≥ 15% increase), overall survival (OS) and transplant-related mortality (TRM), respectively. The median CD34 dose infused was 7.47 × 10/kg (range 3.51 × 10-3.39 × 10/kg). Among patients with PGF who survived ≥ 3 months post-SCB (n = 8), we observed a non-significant decrease in the cumulative median number of red cell transfusions, platelet transfusions, and GCSF but not intravenous immunoglobulin doses in the 3 months before and after SCB. Overall response rate (ORR) was 50%, with 29% complete and 21% partial responses. ORR was better in recipients who received lymphodepletion (LD) pre-SCB versus none (75% versus 40%; p = 0.56). The incidence of acute and chronic graft-versus-host-disease was 7% and 14%, respectively. The 1-year OS was 50% (95% CI 23-72%) and TRM was 29% (95% CI 8-58%). SCB was effective in half of our cohort with possible benefit of LD pre-SCB.

References

Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S . CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant. 2013; 20(3):382-6. DOI: 10.1016/j.bbmt.2013.11.034. View

Forlanini F, Zinter M, Dvorak C, Bailey-Olson M, Winestone L, Shimano K . Hematopoietic Cell Transplantation-Comorbidity Index Score Is Correlated with Treatment-Related Mortality and Overall Survival following Second Allogeneic Hematopoietic Cell Transplantation in Children. Transplant Cell Ther. 2021; 28(3):155.e1-155.e8. DOI: 10.1016/j.jtct.2021.11.015. View

Slatter M, Bhattacharya A, Abinun M, Flood T, Cant A, Gennery A . Outcome of boost haemopoietic stem cell transplant for decreased donor chimerism or graft dysfunction in primary immunodeficiency. Bone Marrow Transplant. 2005; 35(7):683-9. DOI: 10.1038/sj.bmt.1704872. View

Mainardi C, Ebinger M, Enkel S, Feuchtinger T, Teltschik H, Eyrich M . CD34 selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. Br J Haematol. 2017; 180(1):90-99. DOI: 10.1111/bjh.15012. View

Yonkof J, Basu A, Redmond M, Dobbs A, Perelygina L, Notarangelo L . Refractory, fatal autoimmune hemolytic anemia due to ineffective thymic-derived T-cell reconstitution following allogeneic hematopoietic cell transplantation for hypomorphic RAG1 deficiency. Pediatr Blood Cancer. 2022; 70(5):e30183. PMC: 10038854. DOI: 10.1002/pbc.30183. View

Haines H, Bleesing J, Davies S, Hornung L, Jordan M, Marsh R . Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. Biol Blood Marrow Transplant. 2014; 21(2):288-92. DOI: 10.1016/j.bbmt.2014.10.010. View

Prabahran A, Koldej R, Chee L, Ritchie D . Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation. Blood Adv. 2021; 6(6):1947-1959. PMC: 8941468. DOI: 10.1182/bloodadvances.2021004537. View

Rangarajan H, Crowell S, Towerman A, Shenoy S . CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease. Bone Marrow Transplant. 2022; 57(10):1592-1594. DOI: 10.1038/s41409-022-01749-9. View

Ghobadi A, Fiala M, Ramsingh G, Gao F, Abboud C, Stockerl-Goldstein K . Fresh or Cryopreserved CD34-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2017; 23(7):1072-1077. PMC: 5515540. DOI: 10.1016/j.bbmt.2017.03.019. View

10.

Cuadrado M, Szydlo R, Watts M, Patel N, Renshaw H, Dorman J . Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function. Haematologica. 2020; 105(11):2639-2646. PMC: 7604618. DOI: 10.3324/haematol.2019.226340. View

11.

Frey N, Porter D . Graft-versus-host disease after donor leukocyte infusions: presentation and management. Best Pract Res Clin Haematol. 2008; 21(2):205-22. PMC: 2504712. DOI: 10.1016/j.beha.2008.02.007. View

12.

Oyekunle A, Koehl U, Schieder H, Ayuk F, Renges H, Fehse N . CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation. Cytotherapy. 2006; 8(4):375-80. DOI: 10.1080/14653240600735784. View

13.

Marotta S, Marano L, Ricci P, Cacace F, Frieri C, Simeone L . Eltrombopag for post-transplant cytopenias due to poor graft function. Bone Marrow Transplant. 2019; 54(8):1346-1353. DOI: 10.1038/s41409-019-0442-3. View

14.

Fraint E, Farooki S, Klein E, Mauguen A, Prockop S, Scaradavou A . Durable Engraftment and Excellent Overall Survival After CD34-Selected Peripheral Blood Stem Cell Boost in Pediatric Patients With Poor Graft Function Following Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2022; 29(1):46.e1-46.e6. PMC: 9825630. DOI: 10.1016/j.jtct.2022.09.027. View

15.

Zimmerman C, Shenoy S . Chimerism in the Realm of Hematopoietic Stem Cell Transplantation for Non-malignant Disorders-A Perspective. Front Immunol. 2020; 11:1791. PMC: 7438804. DOI: 10.3389/fimmu.2020.01791. View

16.

Berger M, Faraci M, Saglio F, Giardino S, Ernestina Vassallo E, Prete A . CD34+ selected peripheral blood Stem Cell Boost (SCB) for Poor Graft Function (PGF) or mixed chimerism in pediatric patients, after hematopoietic stem cell transplantation: Results of a retrospective multicenter study. Pediatr Transplant. 2020; 25(5):e13909. DOI: 10.1111/petr.13909. View

17.

Kharfan-Dabaja M, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R . Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and.... Transplant Cell Ther. 2021; 27(8):642-649. DOI: 10.1016/j.jtct.2021.04.007. View

18.

Glucksberg H, Storb R, Fefer A, Buckner C, Neiman P, Clift R . Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974; 18(4):295-304. DOI: 10.1097/00007890-197410000-00001. View

19.

Haen S, Schumm M, Faul C, Kanz L, Bethge W, Vogel W . Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation. J Cancer Res Clin Oncol. 2015; 141(12):2241-51. DOI: 10.1007/s00432-015-2027-x. View

20.

Jagasia M, Greinix H, Arora M, Williams K, Wolff D, Cowen E . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2014; 21(3):389-401.e1. PMC: 4329079. DOI: 10.1016/j.bbmt.2014.12.001. View